The AHEAD-MERIT clinical trial will take place in 15 hospitals in England, targeting patients with aggressive human papillomavirus (HPV)-associated cancers. These cancers have high rates of recurrence and poor survival. The vaccine being developed targets proteins commonly found in HPV-associated head and neck cancer. The health secretary declared the initiative a "huge victory" and NHS England is working with BioNTech to identify eligible patients. This is the third trial under the NHS Cancer Vaccine Launch Pad, which has already supported 550 patients.
Sources
Latest News
18:04
Cristela Georgescu sent a “clarification” message regarding the postponement of the Ilfov Tribunal’s decision in her husband’s case
17:56
Constantin Toma calls for changes to the public procurement law and a reduction in bureaucracy, warning that delays are blocking local investments
17:49
Radu Oprea reaffirms Romania’s support for Ukraine and calls for increased security in the Black Sea
17:39
An AfD leader invites Elon Musk to invest in the state of Saxony-Anhalt and promises “favorable conditions for business”
17:29
Sorina Pintea, sentenced to three years and six months in prison for bribery, could be released on parole
See more news